Q-omics provides the consensus-scored SERPINA6 profile across patient tissues and cancer cell-line models. SERPINA6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SERPINA6 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, SERPINA6 protein abundance shows 25,970 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, KICH, and LSCC as cancer lineages where SERPINA6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SERPINA6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SERPINA6 survival associations across molecular data types. SERPINA6 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SERPINA6 RNA expression–survival associations across cancer types. High SERPINA6 expression shows unfavorable associations in CHOL and THCA, but favorable associations in KIRC, UCEC, BRCA and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SERPINA6 RNA expression.
This table summarizes SERPINA6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SERPINA6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SERPINA6 shows lower tumor expression in KICH, LUAD, KIRC, CHOL and COAD and higher tumor expression in THCA. The KICH box plot shows higher SERPINA6 RNA expression in normal versus tumor tissue (log2 FC = −5.895, t-test p < 0.001).
This table shows molecular features associated with SERPINA6 in patient tissues and cancer cell lines. In patient samples, SERPINA6 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SERPINA6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LIVER.
